Published in N Engl J Med on April 26, 1984
Metabolism and possible health effects of aluminum. Environ Health Perspect (1986) 1.64
In vivo skeletal response and biomechanical assessment of two novel polyalkenoate cements following femoral implantation in the female New Zealand White rabbit. J Mater Sci Mater Med (1998) 0.99
Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts. Crit Rev Toxicol (2014) 0.90
The nervous system and chronic kidney disease in children. Pediatr Nephrol (2004) 0.89
Water content of aluminum, dialysis dementia, and osteomalacia. Environ Health Perspect (1985) 0.86
Do aluminium-based phosphate binders continue to have a role in contemporary nephrology practice? BMC Nephrol (2011) 0.86
Histological and electron microprobe studies of mineralisation in aluminium-related osteomalacia. J Clin Pathol (1992) 0.81
Suppression of secondary hyperparathyroidism in children with chronic renal failure by high dose phosphate binders: calcium carbonate versus aluminium hydroxide. Br Med J (Clin Res Ed) (1985) 0.77
Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med (1974) 4.23
Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int (2000) 3.29
Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med (1989) 2.40
Determinants of type and timing of initial permanent hemodialysis vascular access. Kidney Int (2000) 1.94
Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest (1987) 1.74
Reversal of adynamic bone disease by lowering of dialysate calcium. Kidney Int (2006) 1.57
Symptomatology, pathophysiology and treatment of the transurethral resection of the prostate syndrome. Br J Urol (1973) 1.53
Etappenlavage: advanced diffuse peritonitis managed by planned multiple laparotomies utilizing zippers, slide fastener, and Velcro analogue for temporary abdominal closure. World J Surg (1990) 1.48
Risk factors for hip fracture among patients with end-stage renal disease. Kidney Int (2000) 1.44
Osteonecrosis in patients receiving dialysis: report of two cases and review of the literature. J Rheumatol (1990) 1.40
Parenteral drug products containing aluminum as an ingredient or a contaminant: response to FDA notice of intent. ASCN/ASPEN Working Group on Standards for Aluminum Content of Parenteral Nutrition Solutions. Am J Clin Nutr (1991) 1.39
Histological quantitation of aluminum in iliac bone from patients with renal failure. J Lab Clin Med (1982) 1.37
Comparison of clinic and home blood pressure levels in essential hypertension and variables associated with clinic-home differences. J Chronic Dis (1980) 1.33
Hypercalcemia, hypercalciuria, medullar nephrocalcinosis, and renal insufficiency in a toddler with Down syndrome. Pediatr Nephrol (1995) 1.33
Human bone cells in culture metabolize 25-hydroxyvitamin D3 to 1,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3. J Biol Chem (1981) 1.33
Carcinoma of the sigmoid colon: an unusual cause of Fournier's gangrene. J Urol (1992) 1.32
The prevalence of bone aluminum deposition in renal osteodystrophy and its relation to the response to calcitriol therapy. N Engl J Med (1982) 1.30
Anthropometric measures and risk of death in children with end-stage renal disease. Am J Kidney Dis (2000) 1.29
Bone aluminum and histomorphometric features of renal osteodystrophy. J Clin Endocrinol Metab (1982) 1.26
Bone disease in burn patients. J Bone Miner Res (1993) 1.23
Temporary abdominal closure (TAC) for planned relaparotomy (etappenlavage) in trauma. J Trauma (1990) 1.23
Avascular necrosis of bone in systemic lupus erythematosus. J Pediatr (1974) 1.23
High incidence of neoplasia in uremic patients receiving long-term dialysis. Cancer and long-term dialysis. Nephron (1981) 1.21
Regulation of glutamine metabolism in vitro by bicarbonate ion and pH. J Clin Invest (1969) 1.17
Cortical fibrinolytic activity in normal and diseased human kidneys. J Lab Clin Med (1972) 1.14
Quantitative histological studies on the pathogenesis of uremic bone disease. J Clin Endocrinol Metab (1974) 1.13
Peritoneal dialysis fluid as a source of hepatitis antigen. Nephron (1981) 1.13
Avascular necrosis following bone marrow transplantation: a case-control study. Bone (1998) 1.11
Development of insulin-dependent diabetes mellitus during the hemolytic-uremic syndrome. J Pediatr (1982) 1.09
Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Am J Kidney Dis (1995) 1.09
Control of clofibrate toxicity in uremic hypertriglyceridemia. Clin Pharmacol Ther (1977) 1.08
Aplastic osteodystrophy without aluminum: the role of "suppressed" parathyroid function. Kidney Int (1993) 1.08
Lithium-induced hyperparathyroidism: an alteration of the "set-point". Ann Intern Med (1982) 1.08
Septic arthritis in hemodialyzed patients. Nephron (1980) 1.08
Assessment of a policy to reduce placement of prosthetic hemodialysis access. Kidney Int (2001) 1.02
Bone density loss after allogeneic hematopoietic stem cell transplantation: a prospective study. Biol Blood Marrow Transplant (2001) 1.01
In vitro detection of endothelial cell damage using 2-deoxy-D-3H-glucose: comparison with chromium 51, 3H-leucine, 3H-adenine, and lactate dehydrogenase. J Lab Clin Med (1985) 1.00
Use of the deferoxamine infusion test in the diagnosis of aluminum-related osteodystrophy. Ann Intern Med (1984) 1.00
Outcome after major renovascular injuries: a Western trauma association multicenter report. J Trauma (2000) 1.00
Aluminum loading during total parenteral nutrition. Am J Clin Nutr (1982) 0.99
Basement membrane nephropathy: a new classification for Alport's syndrome and asymptomatic hematuria based on ultrastructural findings. Hum Pathol (1983) 0.98
Purine excretion during tumor lysis in children with acute lymphocytic leukemia receiving allopurinol: relationship to acute renal failure. J Pediatr (1986) 0.98
Fibrinolytic treatment of the haemolytic-uraemic syndrome. Lancet (1972) 0.97
Effects of dietary caffeine on renal handling of minerals in adult women. Life Sci (1990) 0.97
Renal cortical fibrinolytic activity in the rabbit following one or two doses of endotoxin. Thromb Diath Haemorrh (1973) 0.96
Aluminum--much ado about something. N Engl J Med (1991) 0.94
Acute diphenylhydantoin intoxication. Am J Dis Child (1968) 0.94
Diagnosis, treatment, and outcome of blunt carotid arterial injuries. Am J Surg (1999) 0.94
Response of crescentic Henoch-Schoenlein purpura nephritis to corticosteroid and azathioprine therapy. Clin Nephrol (1998) 0.94
Increased serum 1,25-dihydroxyvitamin D in idiopathic hypercalciuria. J Lab Clin Med (1977) 0.93
Treatment of severe IgA nephropathy in children. Pediatr Nephrol (1989) 0.92
Acute respiratory distress in a child after steroid-induced pancreatitis. Pediatrics (1978) 0.92
Screening plasma aluminum levels in relation to aluminum bone disease among asymptomatic dialysis patients. Am J Kidney Dis (1999) 0.92
Role of glutathione in protecting endothelial cells against hydrogen peroxide oxidant injury. J Lab Clin Med (1986) 0.92
Blood pressure reductions during self-recording of home blood pressure. Am Heart J (1979) 0.91
A burr-like device to facilitate temporary abdominal closure in planned multiple laparotomies. Eur J Surg (1993) 0.91
Acute renal failure. N Engl J Med (1996) 0.91
Nephrolithiasis in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr (1985) 0.90
Bone disease associated with total parenteral nutrition. Lancet (1980) 0.90
Periarticular tumoral calcinosis and hypercalcemia in a hemodialysis patient without hyperparathyroidism: a case report. J Nucl Med (1990) 0.89
Aluminum as a factor in the bone disease of long-term parenteral nutrition. Trans Assoc Am Physicians (1982) 0.89
1,25-dihydroxycholecalciferol. Effect on skeletal lesions and plasma parathyroid hormone levels in uremic osteodystrophy. Arch Intern Med (1974) 0.89
A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Rapid communication. Kidney Int (1998) 0.89
Dietary and behavioral risk factors for urolithiasis: potential implications for prevention. Am J Kidney Dis (1996) 0.88
Carpal tunnel syndrome in chronic renal dialysis patients. Arch Phys Med Rehabil (1981) 0.88
Burn-associated bone disease in sheep: roles of immobilization and endogenous corticosteroids. J Burn Care Rehabil (1997) 0.88
Vitamin D intoxication in an anephric child. Ann Intern Med (1975) 0.88
Evidence that serum phosphate is independently associated with serum PTH in patients with chronic renal failure. Am J Kidney Dis (1997) 0.87
Generalized Shwartzman reaction in the rabbit. Immunopathologic findings in the kidney. Arch Pathol (1974) 0.87
Failure of cobra venom factor to prevent the generalized Shwartzman reaction and loss of renal cortical fibrinolytic activity. Am J Pathol (1974) 0.86
Glomerular fibrinolytic activity following endotoxin-induced glomerular fibrin deposition in the pregnant rat. Am J Pathol (1974) 0.86
Clinical and laboratory features of aluminum-related bone disease: differences between sporadic and "epidemic" forms of the syndrome. Am J Kidney Dis (1985) 0.85
Serum immunoreactive parathyroid hormone and 25-hydroxyvitamin D in patients with uremic bone diseases. J Clin Endocrinol Metab (1975) 0.85
Vitamin-D-resistant osteomalacia in hemodialysis patients lacking secondary hyperparathyroidism. Ann Intern Med (1981) 0.85
Infections in haemodialysis patients. Lancet (1970) 0.85
Use of calcium carbonate as a phosphate binder in dialysis patients. Miner Electrolyte Metab (1986) 0.84
Aluminum is associated with low bone formation in patients receiving chronic parenteral nutrition. Ann Intern Med (1983) 0.84
Dimensional accuracy of improved dental stone and epoxy resin die materials. Part I: Single die. J Prosthet Dent (1997) 0.84
Response of type I membranoproliferative glomerulonephritis to pulse methylprednisolone and alternate-day prednisone therapy. Pediatr Nephrol (1995) 0.83
Prevalence of serum lipid abnormalities in chronic hemodialysis. Metabolism (1977) 0.83
Aluminum-associated bone disease in chronic renal failure: high prevalence in a long-term dialysis population. J Bone Miner Res (1986) 0.83
IgA nephropathy databank: development of a system for management of renal biopsy acquired data. Am J Kidney Dis (1997) 0.83
Effects of 1-week head-down tilt bed rest on bone formation and the calcium endocrine system. Aviat Space Environ Med (1992) 0.83
Development and reversibility of aluminum-induced bone lesion in the rat. J Lab Clin Med (1987) 0.83
Post-and-core assemblies made with an accelerated pattern elimination technique. J Prosthodont (1994) 0.83
Longitudinal evaluation of transport kinetics in children receiving peritoneal dialysis. Pediatr Nephrol (1999) 0.82
Symptomatic hypercalcemia of immobilization in a patient with end-stage renal disease. Am J Kidney Dis (2000) 0.82
Shock-associated right colon ischemia and necrosis. J Trauma (1995) 0.82
Immunofluorescent localization of factor VIII-related antigen and fibrinogen in hyperacute xenograft rejection and in the Shwartzman reaction in the rat. Clin Immunol Immunopathol (1978) 0.82
Inert gas analysis of ventilation-perfusion matching during hemodialysis. J Clin Invest (1984) 0.82
Adipose tissue lipoprotein lipase in chronic hemodialysis: role in plasma triglyceride metabolism. J Clin Endocrinol Metab (1978) 0.82
Controlled prospective randomized comparison of high-frequency jet ventilation and conventional ventilation in neonates with respiratory failure and persistent pulmonary hypertension. J Perinatol (1997) 0.82
Comparison of three methods of rewarming from hypothermia: advantages of extracorporeal blood warming. J Trauma (1991) 0.82
Acute rhabdomyolysis associated with hemolytic-uremic syndrome. J Pediatr (1983) 0.81
Use of 1,25(OH)2-vitamin D3 to separate 'types' on renal osteodystrophy. Proc Eur Dial Transplant Assoc (1977) 0.81